EPHB4-CAR-T cells displayed strong sustained killing activity against Rh30 tumor cells (Figures 2B, 2C, and S3B) and continuous proliferation (Figure 2D) even following multiple tumor rechallenge, which indicated that antitumor efficacy was not reduced due to immune evasion, a condition often observed in virally engineered CAR-T cells.29 This evidence concerns the gene EPHB4 and neoplasm.